Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBC Induction in BRAF V600E MSS Colorectal Cancer
NCT06207656Phase 2Recruiting
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Apr 2024
- Primary completion
- Apr 2029
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib, cetuximab in colorectal cancer (CRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Started Apr 2024; status: recruiting.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06207656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207656.